Tormere Analytics
OverviewStock ResearchPortfolio LabOptions LabCalculatorsWatchlist
Data Explorer
Pricing
Privacy PolicyTerms of Service

MBRX

$0.83+8.48%

Moleculin Biotech, Inc.

Market Cap
$15M
Sector
Materials
Industry
Biotechnology
Beta
1.99
5yr monthly vs SPY
Price Chart
Loading…

Signals

Insider Velocity
25.6x
buying
Congress
—
recent trades
Short Volume
41%
W/W +16.5pp

Market & Alt Data

News
11
recent articles
Activist
—
none active
Analyst Consensus
Strong Buy
9 analysts
Velocity Score
25.65x
Current Rate (90d)
11111.10/mo
Baseline Rate
0.00/mo
Unique Buyers (90d)
3
Sort by
Type
Trade DateFiledOwnerRoleTypeSharesPriceValueOwned After
2026-08-032026-08-05Foster Jonathan P.Chief Financial OfficerPurchase293.3K——305.7KView
2026-08-032026-08-05KLEMP WALTER VDirector & CEO and PresidentPurchase533.3K——564.3KView
2026-08-032026-08-05PICKER DONALD HChief Science OfficerPurchase173.3K——174.1KView

Recent News

HC Wainwright & Co. Maintains Buy on Moleculin Biotech, Lowers Price Target to $3
Benzinga · 2026-08-28
Moleculin CEO, Walter Klemp, Participates in the Virtual Investor “Why Now” On-Demand Conference
Yahoo · 2026-08-27
Moleculin Biotech (MBRX) Upgraded to Buy: Here's Why
Yahoo · 2026-08-24
Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trial
Yahoo · 2026-08-14

Informational purposes only, not investment advice.

Moleculin Biotech Q2 EPS $(1.40) Misses $(1.01) Estimate
Benzinga · 2026-08-14
Moleculin Announces Pricing of $9.3 Million Public Offering
Yahoo Finance · 2026-07-31
Moleculin’s MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients
Yahoo Finance · 2026-07-31
Moleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor "What This Means" Segment
Yahoo Finance · 2026-07-06
MBRX Stock Drops 25% As Moleculin Biotech's Interim Cancer Trial Data Falls Short Of Significance
Yahoo Finance · 2026-06-30
Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than Control
Yahoo Finance · 2026-06-30
Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor “What This Means” Segment
Yahoo Finance · 2026-06-04

Factor Profile

Pro
Pro feature

Fama-French factor analysis is available on the Pro plan.

Upgrade to Pro →
Pipeline
Phase 2
2 active trials